WO2000077251A2 - Forensic dna profiling method comprising immunological separation step - Google Patents

Forensic dna profiling method comprising immunological separation step Download PDF

Info

Publication number
WO2000077251A2
WO2000077251A2 PCT/GB2000/002203 GB0002203W WO0077251A2 WO 2000077251 A2 WO2000077251 A2 WO 2000077251A2 GB 0002203 W GB0002203 W GB 0002203W WO 0077251 A2 WO0077251 A2 WO 0077251A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
spermatozoa
antibody
antibodies
sperm
Prior art date
Application number
PCT/GB2000/002203
Other languages
French (fr)
Other versions
WO2000077251A3 (en
Inventor
Matthew James Greenhalgh
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Priority to AU52356/00A priority Critical patent/AU5235600A/en
Publication of WO2000077251A2 publication Critical patent/WO2000077251A2/en
Publication of WO2000077251A3 publication Critical patent/WO2000077251A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/367Infertility, e.g. sperm disorder, ovulatory dysfunction

Definitions

  • the present invention relates to improvements in forensic science and in particular to analytical methods for determining the identity of DNA from mixed samples.
  • the forensic biologist is mainly concerned with identifying trace evidence such as blood, semen, saliva and hairs found at the scene of crimes such as murder, rape and assault.
  • DNA profiling has provided a means of identifying the source of such material with a very high degree of certainty.
  • the possibility of a chance match between samples is often presented in court as "less than 1 in a 1000 million", although in reality it can be even rarer. More importantly it is possible to conclusively exclude a suspect as the possible source of a body fluid thus eliminating them from a police inquiry.
  • a DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody- epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.
  • specific characteristics of the isolated DNA we include all characteristics of the DNA and nucleotide sequence(s) therein, such as STRs or VNTRs as may be used to determine the identity of the isolated DNA.
  • the epithelial cells are generally female epithelial cells and usually vaginal epithelial cells.
  • Any convenient DNA profiling method may be used. These include methods such as short tandem repeat (STR) profiling or profiling using multilocus or single locus probes such as disclosed in European patents nos. 186271 and 238329 respectively. Alternatively the minisatellite variant repeat (MVR) profiling method disclosed in European patent no. 530009 may be used. Convenient and preferred methods include the use of commercially available STR kits such as Profiler PlusTM and PowerPlexl ⁇ TM designed to fulfil the requirements of, for example, the US and European courts. Any convenient antibodies may be used provided they are specific for their target antigens. A particular antigen is the FA-2 antigen, this is a sperm specific protein to which monoclonal antibodies (Vic-1) have been raised.
  • STR short tandem repeat
  • MVR minisatellite variant repeat
  • Convenient and preferred methods include the use of commercially available STR kits such as Profiler PlusTM and PowerPlexl ⁇ TM designed to fulfil the requirements of, for example, the US and European courts.
  • Any convenient antibodies
  • the Vic-1 monoclonal antibody completely blocks human SPA (Sperm Penetration Assay of zona free hamster oocytes), and reduces acrosome reaction and release of acrosin activity. Binding of the antibody does not affect motility of the sperm.
  • the antibody S 19 target epitope SAGA-1 (A.B. Diekman et al. (1999) FASEB J. 13, 1303- 1313) may be used to bind to all surfaces of the human sperm.
  • Separation of the antibody-spermatozoa and/or antibody-endothelial cell complexes from other DNA in the sample may be achieved by any convenient technique. These include agglutination and solid phase capture methods.
  • a particular complex may be targeted and captured by antibodies bound directly or indirectly to a solid phase.
  • the solid phase may for example be part of a reaction vessel such as a PCR reaction vessel or it may be a bead or particle such as a magnetic bead.
  • sperm heads may be induced to agglutinate through use of, for example an IgG antibody targeted against the antigen and an IgM antibody raised against the invariant portion of the IgG antibody.
  • the complex formed may be harvested by centrifugation or filtration.
  • a DNA profiling method which comprises (i) contacting a sample believed to comprise both spermatozoa and epithelial cells with antibodies specific for antigens presented on the spermatozoa and epithelial cells respectively which antigens are not readily degraded, so as to form antibody-spermatozoa and antibody-epithelial cell complexes respectively, (ii) separating the complexes from other material in the sample, (iii) isolating DNA from one or both complexes and (iv) determining the specific characteristics of the isolated DNA.
  • Figure 1 shows an intact sperm complete with tail
  • Figure 2 shows a discrete head alone
  • Figure 3 shows the situation where the acrosome at the tip of the sperm head has burst, releasing lytic activity
  • Figure 4 shows a p ⁇ mary antibody interacting with the antigen, which in turn provides a binding site (biotin) for the Streptavidin coated magnetic particles
  • Figure 5 shows a p ⁇ mary antibody interacting with the antigen, which in turn provides a binding site for the secondary antibody
  • Figure 6 shows the p ⁇ mary antibody linked directly to a magnetic bead, simplifying the linking of the antigen and the magnetic bead,
  • Figure 7 shows the gel electrophoresis results of the DNA profiling method of the invention illustrated for convenience at a single genetic locus
  • Lane 1 is a control profiling reaction using blood taken from the male suspect
  • lane 2 is from spermatozoa from the male suspect
  • lane 3 is from epithelial matenal from the female victim
  • lane 4 is a control profiling reaction using blood from the female victim It can be seen there is positive identification of the male and female DNA
  • a p ⁇ mary antibody is applied to the cell mixture
  • the antibodies used as the p ⁇ mary will be either (a) biotinylated, or (b) of a species and sub-class, for which there is a commercially available antibody conjugated directly to a magnetic bead, or (c) linked directly to a solid support such as the wall of a tube, or a magnetic bead
  • the p ⁇ mary antibody binds to the sperm antigen to form a stable conjugate
  • the conjugate is then ret ⁇ eved from solution by means of (a) Streptavidin linked magnetic beads, or (b) magnetic beads coated with antibodies with affinity for
  • a immunogenic species unique to the sperm, and is present on all the surfaces above then it may be used as the target for the primary antibody.
  • an antigen presented on the main body of the sperm head may be adequate.
  • the antigen is bound by the primary antibody which, in turn, provides a binding site for the Streptavidin coated magnetic particles ( Figure 4) or a secondary antibody bound to magnetic particles ( Figure 5).
  • antigens exist which may not have a direct role in binding of the sperm head to the zona pellucida, but which may be of potential use as sperm specific targets.
  • One such antigen is the carbohydrate moiety of a glycoprotein, called SAGA-1 (Sperm Agglutination Antigen- 1). Magnetic Beads
  • Dynal UK produces microscopic, uniform, supe ⁇ aramagnetic, monodispersed polymer beads (DynabeadsTM).
  • the beads are available with a streptavidin coating for conjugation to biotinylated molecules. These beads may be linked to biotinylated antibodies raised against human semen. Alternatively, the beads may be purchased in an activated form which allows the direct coupling of the antibody to the bead.
  • the antibody - bead complex will link to the sperm cells and a magnet is then used to isolate them from the other cell types present in a swab extract.
  • This system has the advantage over current methods of being more specific in isolating spermatozoa prior to DNA extraction. It also produces far cleaner DNA which is less likely to contain PCR inhibitors. Additionally the method requires fewer tube to tube transfers minimising sample loss, contamination and the possibility of operator error. These are all important considerations with forensic samples.
  • a post coital swab is taken from an alleged victim and treated as follows.
  • Cellular material is extracted by vortexing the swab in phosphate buffered saline and the cells harvested by centrifugation. These are re-suspended in a small volume (300 ⁇ l) of phosphate buffered saline and incubated with an excess of an anti-sperm antibody.
  • the antibody-sperm complex formed is then targeted by an excess of the secondary antibody/ magnetic bead complex. (This may also be achieved by having a biotinylated primary antibody being bound by an excess of streptavidin coated magnetic beads).
  • the complex is harvested magnetically and undergoes a series of washes to remove the unbound cellular material. The complex is heated to 80°C to denature the antibodies and release the sperm heads.
  • the DNA can then be extracted by a range of established methods. (Phenol/chloroform, Chelex 100 etc.).
  • STR profiling is then effected using a PE Profiler PlusTM (Profiler Plus Handbook) kit according to manufacturers instructions.
  • the primers, buffer and thermostable DNA polymerase (such as AmpliTaq GoldTM) are added to the PCR tubes (as above).
  • Conveniently 28 cycles of PCR amplification are effected using a 9700 thermal cycler (Perkin Elmer).
  • Lane 1 is a control profiling reaction using blood taken from the male suspect
  • lane 2 is from spermatazoa from the male suspect
  • lane 3 is from epithelial material from the female victim
  • lane 4 is a control profiling reaction using blood from the female victim. It can be seen there is positive identification of the male and female DNA.

Abstract

A DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody-epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.

Description

ASSAYS
The present invention relates to improvements in forensic science and in particular to analytical methods for determining the identity of DNA from mixed samples. The forensic biologist is mainly concerned with identifying trace evidence such as blood, semen, saliva and hairs found at the scene of crimes such as murder, rape and assault. DNA profiling has provided a means of identifying the source of such material with a very high degree of certainty. The possibility of a chance match between samples is often presented in court as "less than 1 in a 1000 million", although in reality it can be even rarer. More importantly it is possible to conclusively exclude a suspect as the possible source of a body fluid thus eliminating them from a police inquiry.
Most of the DNA profiling methods in use today use the high degree of variability in tandem repeat regions of the human genome. In these regions, a core sequence is repeated many times, laid end to end. The exact number of repeats varies greatly between people and consequently the length of the minisatellite region containing the repeats are different in different people. By analysing a series of different tandem repeat loci it possible to generate a DNA profile which is highly specific.
Many forensic samples contain a mixture of body fluids from different individuals This is commonly found in sexual assault cases where vaginal swabs taken from the victim will have a mixture of semen and vaginal epithelia present. To simplify the analysis it is very useful to separate the different cell types and obtain a separate DNA profile for the semen.
Currently the only practical method available for isolation of DNA from mixtures of spermatozoa and vaginal epithelial cells is based on differential (preferential) lysis. This method relies on the greater resistance of sperm heads to digestion over other cellular material. The cellular material is extracted from the sample eg. swab into an extraction buffer. The preparation then undergoes relatively mild digestion to lyse cellular material other than sperm. Centrifugation isolates the intact sperm from the other digested cellular components. The sperm then undergo a more aggressive digestion with a long incubation with Proteinase K and dithiothrietol (DTT) to release the DNA. The above method can be inefficient and often does not produce complete separations.
Subsequent typing of genetic markers will reveal three or four alleles rather than the expected one or two that would result from complete separation of the cells within the mixture. The need therefore exists for further improved methods.
We have now devised novel analytical methods which use immuno-capture of male and/or female genetic material from a mixed sample followed by isolation and analysis of the DNA comprised in the male and/or female genetic material. Therefore in a first aspect of the present invention we provide a DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody- epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.
The development of the above method allows efficient separation of spermatozoa from epithelial cells prior to DNA characterisation, more easily inteφretable typing patterns and the successful individualisation of the spermatozoa and epithelial DNA. By "not readily degraded" we mean that the antigens can be specifically recognised by the antibodies used in the analytical methods of the invention. That is to say the (target) antigens have not been adversely affected at any time prior to or during their use in the methods of the invention.
By "other material in the sample" we include uncomplexed cellular material and other DNA as may be present in the sample.
By "specific characteristics of the isolated DNA" we include all characteristics of the DNA and nucleotide sequence(s) therein, such as STRs or VNTRs as may be used to determine the identity of the isolated DNA.
The epithelial cells are generally female epithelial cells and usually vaginal epithelial cells.
Any convenient DNA profiling method may be used. These include methods such as short tandem repeat (STR) profiling or profiling using multilocus or single locus probes such as disclosed in European patents nos. 186271 and 238329 respectively. Alternatively the minisatellite variant repeat (MVR) profiling method disclosed in European patent no. 530009 may be used. Convenient and preferred methods include the use of commercially available STR kits such as Profiler Plus™ and PowerPlexlό™ designed to fulfil the requirements of, for example, the US and European courts. Any convenient antibodies may be used provided they are specific for their target antigens. A particular antigen is the FA-2 antigen, this is a sperm specific protein to which monoclonal antibodies (Vic-1) have been raised. (R.K.Naz et al. (1993) Biol. Reprod., 49, 1236-1244). The Vic-1 monoclonal antibody completely blocks human SPA (Sperm Penetration Assay of zona free hamster oocytes), and reduces acrosome reaction and release of acrosin activity. Binding of the antibody does not affect motility of the sperm. Alternatively, the antibody S 19 (target epitope SAGA-1) (A.B. Diekman et al. (1999) FASEB J. 13, 1303- 1313) may be used to bind to all surfaces of the human sperm.
Separation of the antibody-spermatozoa and/or antibody-endothelial cell complexes from other DNA in the sample may be achieved by any convenient technique. These include agglutination and solid phase capture methods. By way of non-limiting example a particular complex may be targeted and captured by antibodies bound directly or indirectly to a solid phase. The solid phase may for example be part of a reaction vessel such as a PCR reaction vessel or it may be a bead or particle such as a magnetic bead. Alternatively sperm heads may be induced to agglutinate through use of, for example an IgG antibody targeted against the antigen and an IgM antibody raised against the invariant portion of the IgG antibody. The complex formed may be harvested by centrifugation or filtration.
The use of magnetic beads to separate complexed material is a preferred aspect of the present invention. The use of such beads allows for example complexed material to be concentrated or drawn closer to an immobilised secondary antibody.
In a particular aspect of the invention we provide a DNA profiling method which comprises (i) contacting a sample believed to comprise both spermatozoa and epithelial cells with antibodies specific for antigens presented on the spermatozoa and epithelial cells respectively which antigens are not readily degraded, so as to form antibody-spermatozoa and antibody-epithelial cell complexes respectively, (ii) separating the complexes from other material in the sample, (iii) isolating DNA from one or both complexes and (iv) determining the specific characteristics of the isolated DNA.
The invention will now be illustrated but not limited by reference to the following specific description. Example and Figures wherein:
Figure 1 shows an intact sperm complete with tail;
Figure 2 shows a discrete head alone; Figure 3 shows the situation where the acrosome at the tip of the sperm head has burst, releasing lytic activity,
Figure 4 shows a pπmary antibody interacting with the antigen, which in turn provides a binding site (biotin) for the Streptavidin coated magnetic particles, Figure 5 shows a pπmary antibody interacting with the antigen, which in turn provides a binding site for the secondary antibody,
Figure 6 shows the pπmary antibody linked directly to a magnetic bead, simplifying the linking of the antigen and the magnetic bead,
Figure 7 shows the gel electrophoresis results of the DNA profiling method of the invention illustrated for convenience at a single genetic locus Lane 1 is a control profiling reaction using blood taken from the male suspect, lane 2 is from spermatozoa from the male suspect, lane 3 is from epithelial matenal from the female victim and lane 4 is a control profiling reaction using blood from the female victim It can be seen there is positive identification of the male and female DNA
Specific description:
We descnbe here a novel technique for the separation of spermatozoa from a mixture of seminal and epithelial matenal The method takes advantage of surface-presented antigens on the sperm head which are absent from other cell types Using (preferably) a high affinity monoclonal or (more likely to cause cross reactivity) a polyclonal serum, a pπmary antibody is applied to the cell mixture The antibodies used as the pπmary will be either (a) biotinylated, or (b) of a species and sub-class, for which there is a commercially available antibody conjugated directly to a magnetic bead, or (c) linked directly to a solid support such as the wall of a tube, or a magnetic bead The pπmary antibody binds to the sperm antigen to form a stable conjugate The conjugate is then retπeved from solution by means of (a) Streptavidin linked magnetic beads, or (b) magnetic beads coated with antibodies with affinity for the invaπant portion of the pπmary antibody, or (c) directly harvested by removal of the supernatant of the tube, or harvest of the magnetic bead through an applied magnetic field
The Primary Antibody
Research based around the search for a male contraceptive pill has identified interference of sperm/oocyte fusion as being a promising mechanism This is being achieved through identification of surface presented proteins which are absent from other cell types. Several such proteins, which have been implicated in sperm/egg fusion, have been identified and reported in the literature (Naz and Vanek. Frontiers in Bioscience 3, e39-48, April 30, 1998). In order for a candidate antigen to be of maximal use, it must be present on the surface of the sperm head regardless of the state of preservation of the sperm head. If the swab is taken quickly after the offence and the sample stored under appropriate conditions, the sperm will be intact, complete with tails (Figure 1). If however the sampling is significantly delayed, the tails may separate, leaving discrete head alone (Figure 2). In extreme cases, it may be that the acrosome at the tip of the sperm head will have burst, releasing lytic activity (Figure 3).
If a immunogenic species unique to the sperm, and is present on all the surfaces above, then it may be used as the target for the primary antibody. Alternatively, an antigen presented on the main body of the sperm head may be adequate.
The antigen is bound by the primary antibody which, in turn, provides a binding site for the Streptavidin coated magnetic particles (Figure 4) or a secondary antibody bound to magnetic particles (Figure 5).
If the primary antibody is linked directly to a solid support such as a magnetic bead, the target antigen and magnetic bead are effectively linked directly (Figure 6).
Antigens
Published research lists a number of proteins which may be of use in immuno- contraception, and which may therefore be useful in the immuno-capture of sperm from a seminal/epithelial mixture. The most important step in the fertilisation process is binding of the sperm with the zona pellucida. Although important for a contraceptive vaccine, an unique surface presented antigen of significant immunogenicity will be a candidate for development as an anchor site for immuno-selection of the sperm head.
Other antigens exist which may not have a direct role in binding of the sperm head to the zona pellucida, but which may be of potential use as sperm specific targets. One such antigen is the carbohydrate moiety of a glycoprotein, called SAGA-1 (Sperm Agglutination Antigen- 1). Magnetic Beads
Dynal UK produces microscopic, uniform, supeφaramagnetic, monodispersed polymer beads (Dynabeads™). The beads are available with a streptavidin coating for conjugation to biotinylated molecules. These beads may be linked to biotinylated antibodies raised against human semen. Alternatively, the beads may be purchased in an activated form which allows the direct coupling of the antibody to the bead. The antibody - bead complex will link to the sperm cells and a magnet is then used to isolate them from the other cell types present in a swab extract.
This system has the advantage over current methods of being more specific in isolating spermatozoa prior to DNA extraction. It also produces far cleaner DNA which is less likely to contain PCR inhibitors. Additionally the method requires fewer tube to tube transfers minimising sample loss, contamination and the possibility of operator error. These are all important considerations with forensic samples.
Procedure
We have purchased antibodies against pooled human semen which have been prepared in sheep. The manufacturers (Biogenesis) have purified this product and biotinylated it. This material is incubated with the streptavidin coated Dynal beads to produce the antibody - bead complex. An aliquot of the complex is added to mixed cell suspension which has been extracted from the vaginal swab. This is incubated for a short while to allow the bead - antibody complex to link on to spermatozoa in the suspension. The new bead-antibody-sperm complex is then pulled to the side of the tube using a magnetic concentrator (Dynal). The pellet is re-suspended in fresh buffer and washed several times to remove all traces of epithelial cells. The purified sperm component then undergoes digestion with proteinase K and DTT to liberate the DNA.
Example:
Characterisation of male and female DNA from a mixed forensic sample
A post coital swab is taken from an alleged victim and treated as follows. Cellular material is extracted by vortexing the swab in phosphate buffered saline and the cells harvested by centrifugation. These are re-suspended in a small volume (300μl) of phosphate buffered saline and incubated with an excess of an anti-sperm antibody. The antibody-sperm complex formed is then targeted by an excess of the secondary antibody/ magnetic bead complex. (This may also be achieved by having a biotinylated primary antibody being bound by an excess of streptavidin coated magnetic beads). The complex is harvested magnetically and undergoes a series of washes to remove the unbound cellular material. The complex is heated to 80°C to denature the antibodies and release the sperm heads.
The DNA can then be extracted by a range of established methods. (Phenol/chloroform, Chelex 100 etc.).
STR profiling is then effected using a PE Profiler Plus™ (Profiler Plus Handbook) kit according to manufacturers instructions. The primers, buffer and thermostable DNA polymerase (such as AmpliTaq Gold™) are added to the PCR tubes (as above). Conveniently 28 cycles of PCR amplification are effected using a 9700 thermal cycler (Perkin Elmer).
The resulting material is separated using gel electrophoresis and the results are shown in Figure 7 (for convenience these illustrate the results at one locus only). Lane 1 is a control profiling reaction using blood taken from the male suspect, lane 2 is from spermatazoa from the male suspect, lane 3 is from epithelial material from the female victim and lane 4 is a control profiling reaction using blood from the female victim. It can be seen there is positive identification of the male and female DNA.

Claims

Clai s:
1. A DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody-epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.
2. A method as claimed in claim 1 wherein the antibodies are biotinylated for separation in step (ii).
3. A method as claimed in claim 1 wherein the antibodies are conjugated to magnetic beads for separation in step (ii).
4. A method as claimed in claim 1 wherein secondary antibodies are used for separation in step (ii).
5. A DNA profiling method which comprises (i) contacting a sample believed to comprise both spermatozoa and epithelial cells with antibodies specific for antigens presented on the spermatozoa and epithelial cells respectively which antigens are not readily degraded, so as to form antibody-spermatozoa and antibody-epithelial cell complexes respectively, (ii) separating the complexes from other material in the sample, (iii) isolating DNA from one or both complexes and (iv) determining the specific characteristics of the isolated DNA.
6. A method as claimed in any one of the previous claims wherein the antibodies for at least one antigen are monoclonal.
7. A method as claimed in any one of the previous claims wherein the antibodies have been raised to the FA2 antigen.
8. A method as claimed in any one of claims 1-6 wherein the antibodies have been raised to the Sperm Agglutination Antigen- 1 (SAGA-1).
PCT/GB2000/002203 1999-06-11 2000-06-07 Forensic dna profiling method comprising immunological separation step WO2000077251A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52356/00A AU5235600A (en) 1999-06-11 2000-06-07 Assays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9913556.8 1999-06-11
GBGB9913556.8A GB9913556D0 (en) 1999-06-11 1999-06-11 Assays

Publications (2)

Publication Number Publication Date
WO2000077251A2 true WO2000077251A2 (en) 2000-12-21
WO2000077251A3 WO2000077251A3 (en) 2001-05-25

Family

ID=10855131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002203 WO2000077251A2 (en) 1999-06-11 2000-06-07 Forensic dna profiling method comprising immunological separation step

Country Status (3)

Country Link
AU (1) AU5235600A (en)
GB (1) GB9913556D0 (en)
WO (1) WO2000077251A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320891B2 (en) 2004-09-10 2008-01-22 Promega Corporation Methods and kits for isolating sperm cells
EP2144993A1 (en) * 2007-05-09 2010-01-20 Applied Biosystems, LLC Methods and systems for differential extraction
WO2015189208A1 (en) * 2014-06-11 2015-12-17 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Methods for separating cells

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186271A1 (en) * 1984-11-12 1986-07-02 THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital Method of characterising a test sample of genomic DNA
EP0238329A2 (en) * 1986-03-19 1987-09-23 Zeneca Limited Improvements in genetic probes
US4741998A (en) * 1985-06-05 1988-05-03 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5: a new probe for sexual assault analyses
US5047508A (en) * 1985-06-05 1991-09-10 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5; a new probe for sexual assault analysis
EP0530009A2 (en) * 1991-08-27 1993-03-03 Zeneca Limited Method of characterising genomic DNA
US5436157A (en) * 1989-03-03 1995-07-25 The University Of Virginia Alumni Patents Foundation Human intra-acrosomal sperm antigen
US5605803A (en) * 1989-03-03 1997-02-25 University Of Virginia Alumni Patents Foundation Human sperm diagnostic
WO1998028622A1 (en) * 1996-12-20 1998-07-02 Fodstad Oeystein Method for characterization of abnormal cells
US5830472A (en) * 1996-06-28 1998-11-03 The University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
WO1999042129A1 (en) * 1998-02-23 1999-08-26 University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and application therefor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186271A1 (en) * 1984-11-12 1986-07-02 THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital Method of characterising a test sample of genomic DNA
US4741998A (en) * 1985-06-05 1988-05-03 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5: a new probe for sexual assault analyses
US5047508A (en) * 1985-06-05 1991-09-10 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5; a new probe for sexual assault analysis
EP0238329A2 (en) * 1986-03-19 1987-09-23 Zeneca Limited Improvements in genetic probes
US5436157A (en) * 1989-03-03 1995-07-25 The University Of Virginia Alumni Patents Foundation Human intra-acrosomal sperm antigen
US5605803A (en) * 1989-03-03 1997-02-25 University Of Virginia Alumni Patents Foundation Human sperm diagnostic
EP0530009A2 (en) * 1991-08-27 1993-03-03 Zeneca Limited Method of characterising genomic DNA
US5830472A (en) * 1996-06-28 1998-11-03 The University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
WO1998028622A1 (en) * 1996-12-20 1998-07-02 Fodstad Oeystein Method for characterization of abnormal cells
WO1999042129A1 (en) * 1998-02-23 1999-08-26 University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and application therefor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320891B2 (en) 2004-09-10 2008-01-22 Promega Corporation Methods and kits for isolating sperm cells
US8993292B2 (en) 2007-01-16 2015-03-31 Applied Biosystems Llc Methods and systems for differential extraction
EP2144993A1 (en) * 2007-05-09 2010-01-20 Applied Biosystems, LLC Methods and systems for differential extraction
EP2144993A4 (en) * 2007-05-09 2010-07-28 Life Technologies Corp Methods and systems for differential extraction
WO2015189208A1 (en) * 2014-06-11 2015-12-17 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Methods for separating cells
US10060914B2 (en) 2014-06-11 2018-08-28 Centre Hospitalier Universitaire Vaudois Methods for separating cells

Also Published As

Publication number Publication date
AU5235600A (en) 2001-01-02
GB9913556D0 (en) 1999-08-11
WO2000077251A3 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
US5646001A (en) Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
US7776580B2 (en) Magnetism based rapid cell separation
EP3488239A1 (en) Quantitative massively parallel proteomics
CN103443275B (en) The method of spermanucleic acid is reclaimed by forensic samples
US8017332B2 (en) Magnetic method for recovering nucleic acid from a mixed cell suspension
RU99110373A (en) USE OF ANTI-BODIES AGAINST EMBRYONAL HEMOGLOBIN FOR IDENTIFICATION OF FETAL CELLS
JP2002512252A (en) Reduction of endotoxin in nucleic acid purification
US20080118909A1 (en) Methods and kits for isolating sperm cells
JP2002507116A (en) Isolation of solid phase nucleic acids
NZ537328A (en) Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
WO2001035759A1 (en) Sperm cell selection system
CN109023535B (en) Method for screening DNA coding compound by using antibody to non-recognition marker protein or cell lysate
WO2018010632A1 (en) Method for separating and purifying fetal nucleated red blood cells, and reagent kit
US20080131954A1 (en) Method of Separating Target DNA from Mixed DNA
CN105120986B (en) A step program for nucleic acid purification
US20020151089A1 (en) Separating components of biological samples
WO2000077251A2 (en) Forensic dna profiling method comprising immunological separation step
Kausch et al. Organelle isolation by magnetic immunoabsorption
US20160046927A1 (en) Methods and systems for differential extraction
Booman et al. Sexing bovine embryos with monoclonal antibodies against the HY antigen
WO1995009245A1 (en) Methods for detecting and analyzing individual rare cells in a population
EP0741141A2 (en) Method of purifying ologonucleotide from biological samples
CN103695419B (en) A kind of Viral nucleic acid extraction reagent
US20240018512A1 (en) Method for multi-dimensional analysis of cell epigenomics
DE19919121B4 (en) Multimeric CMV antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP